FTC Interim Report on Pharmacy Middlemen Is First Step of Many Needed in Addressing Drug Costs, AccessAugust 15, 2024Practice Management
FDA Approves Lymphir for R/R Cutaneous T-Cell LymphomaAugust 9, 2024Patient & Survivor CareImmunotherapyLymphoma & Plasma Cell DisordersImmuno-oncologyPractice Management
Immunotherapy May Be Overused in Dying Patients With CancerAugust 8, 2024ImmunotherapyImmuno-oncologyBreast CancerCNS/Brain CancerDLBCLFollicular LymphomaGastroenterology
Tool Can Help Predict Futile Surgery in Pancreatic CancerAugust 7, 2024Gastrointestinal CancerGastroenterologyPatient & Survivor CareMixed TopicsPractice Management
Government Accuses Health System of Paying Docs Outrageous Salaries for Patient ReferralsAugust 5, 2024Practice Management
FDA Approves First Engineered Cell Therapy for a Solid TumorAugust 2, 2024Sarcoma & GISTPatient & Survivor CareCNS/Brain CancerNeuro-oncologyNonmelanoma Skin CancerMetastatic Breast CancerPractice Management
FDA Expands Darzalex Faspro Indication in MyelomaAugust 2, 2024Patient & Survivor CarePractice Management
The Last 30 Days: How Oncologists’ Choices Affect End-of-Life Cancer CareAugust 2, 2024Patient & Survivor CarePractice ManagementGastrointestinal CancerGastroenterologyGenitourinary CancerGynecologic CancerBreast Cancer
Insurers’ Rules and AI for Preauthorization: ‘Ethically Nuts,’ Says EthicistAugust 1, 2024Practice Management
FDA Calls AstraZeneca’s NSCLC Trial Design Into QuestionJuly 30, 2024Lung CancerPractice ManagementPatient & Survivor Care
Greater Transparency of Oncologists’ Pharma Relationships NeededJuly 22, 2024Practice ManagementPatient & Survivor CarePreventive CareBreast CancerCNS/Brain CancerDLBCLDiversity in Medicine
